Navigation Links
Reportlinker Adds Pharmaceutical Key Trends 2011 - Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions
Date:5/11/2011

NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions

http://www.reportlinker.com/p0491917/Pharmaceutical-Key-Trends-2011-–-Generics-Market-Overview-Patent-cliff-set-to-drive-global-generic-uptake-despite-tougher-market-conditions.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_and_Supplement

Introduction

The combined generics market size is valued at approximately $77bn in the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), the BRIC markets (Brazil, Russia, India, and China), and Australia combined. With branded pharma set to lose approximately $100bn in sales due to the patent cliff, this presents a significant opportunity for generics players during 2011–15.

Features and benefits

* An overview generic uptake and market sizing

* Insight into the key drivers and resistors to generic uptake in key the developed and emerging markets.

* An examination of the major generics players and the strategies they have implemented in both the developed and emerging markets.

* Insight into future opportunities for generics players

Highlights

In response to rising healthcare expenditure, governments in developed markets are looking bolster generic uptake in order to contain costs. Physician prescribing by international non-proprietary name (INN), in addition to automatic substitution and pharmacist incentives, are key tools to drive generic uptake.

In the US, despite the addition of many new customers and the continued drive to increase generic uptake as a result of the healthcare reform law, generics companies are set to experience further downward pricing pressures and will be forced to operate with ever-decreasing margins, focusing on consolidation and cost-cutting.

The BRIC countries represent a key growth market for the generics industry. Uptake of generics in these markets will be driven by continued population expansion, increased prosperity, and expanding healthcare coverage.

Your key questions answered

* Evaluate the drivers and resistors to generic uptake in the US, EU, Japan and BRIC markets

* Gain insight into the deal types between companies to bolster their position in generics markets

* Identify which key small molecules are facing patent expiry and provide opportunities for generic producers

Executive Summary

Key findings

Prescription pharmaceuticals sales and growth rate analysis, 2003–15

Operating costs and profit analysis

Shionogi: PharmaVitae forecasts at a glance

Strategic insight

Focus on "core strategic" product lines

Late-stage pipeline products Shionogi's launch portfolio consists of 10 products, six of which have already come to market – Cymbalta, Pirespa (pirfenidone), Rapiacta (peramivir), Kapvay (clonidine hydrochloride), and Cuvposa (glycopyrrolate) – indicating its success in launching late-stage products. Furthermore, over 2009–15, Shionogi plans to file New Drug Applications (NDAs) for at least four late-stage pipeline products (S-349572, S-474474, Ospemifene, and PSD502), and potentially more products if possible.

Global expansion

CNS, ID and CV focus

Decreased emphasis on non-pharmaceuticals business

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

ABOUT THIS PROFILE

PharmaVitae Explorer database

Chapter structure Executive summary

Company introduction

Company sales

Company financials

Key products

Data sourcing

Analyst consensus

QUARTERLY NEWS UPDATE

Key findings

Latest quarterly sales

Q4 2009 Shionogi: rapid Japanese approval represents important milestone for peramivir

Q2 2009

Latest prescription pharma product news

Q3 2010

Q2 2010

Q1 2010

Q4 2009

Q3 2009

Latest corporate news

Q3 2010

Q2 2009

Q1 2009

Q4 2009

Q3 2009

Future product milestones

COMPANY INTRODUCTION

Key findings

Background

Key corporate developments

M&A history Shionogi and Eli Lilly capsule business

[Missing title]

Current corporate structure

Pharmaceuticals Shionogi is primarily focused on its pharmaceuticals business, which accounts for more than 90% of its total net sales. Crestor (rosuvastatin) is a key contributing product to Shionogi's pharmaceuticals segment. A "superstatin", Crestor, was developed in-house by Shionogi and then out-licensed to AstraZeneca in 1998. AstraZeneca has worldwide marketing exclusivity, except in Japan where the product is co-promoted by the two companies.

Consumer health Shionogi has a small consumer health division, which concerns itself predominantly with the sale of OTC products. These are generally analgesics, antipyretics, vitamins, and minerals. Key products include: the Sedes range‚ a brand of analgesics; Pylon‚ a cold remedy brand; and Popon‚ a family of vitamin compounds. Shionogi has recently expanded its Popon brand‚ adding new formulations to the line. Popon B (muscle fatigue) and Popon Pumeri (eye fatigue) were launched in 2009. In addition to OTC medications‚ Shionogi also markets the Correct brand of denture products.

Diagnostics

COMPANY SALES

Key findings

Prescription pharmaceuticals sales and growth rate analysis, 2003–15

Product analysis

Product analysis, 2003–09

Product analysis, 2009–15

Therapy area analysis

Geographic analysis

Launch/core/expiry analysis

Explanation of launch/core/expiry analysis

Launch analysis, 2009-15

Core analysis, 2009-15

Expiry analysis, 2009-15

Launch/core/expiry configuration, 2009–15

Molecule type analysis

Externalization analysis

COMPANY FINANCIALS

Key findings

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2003–09

Operating costs and profit analysis

Operating costs and profit analysis, 2003–09

Operating cost ratio and profit margin analysis, 2003–09

Operating cost ratio and profit margin analysis, 2009–15

Operating costs and profit analysis, 2009–15

KEY PRODUCTS

Key findings

Overview

Cardiovascular

[Missing title]

Irbetan

Central nervous system

[Missing title]

Infectious disease

Flomox

S-349572

APPENDIX

References

Abbreviations

Exchange rates

To order this report:

Vitamin and Supplement Industry: Pharmaceutical Key Trends 2011 – Generics Market Overview: Patent cliff set to drive global generic uptake despite tougher market conditions

Vitamin and Supplement Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Markets for Emerging Pharmaceutical Technologies
2. Reportlinker Adds Orthopedic Devices Market in the Emerging Countries (China, India, Brazil) - Presenting New Avenues for Growth and Profitability
3. Reportlinker Adds Medical Imaging Reports Bundle
4. Reportlinker Adds Fetal Monitoring, Diagnostics and Predictive Tests
5. Reportlinker Adds KOL insights and unmet needs in Ulcerative Colitis and Crohns Disease
6. Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
7. Reportlinker Adds Brazil Biomaterial Market (2010 - 2015)
8. Reportlinker Adds Minimally Invasive Surgical Devices, World Market
9. Reportlinker Adds Triple Analysis: Breast Cancer, Leukemia and Cancer Vaccines
10. Reportlinker Adds Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
11. Reportlinker Adds European Market for Cardiac Rhythm Management, Electrophysiology & Ablation Devices 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
(Date:2/4/2016)... Feb. 4, 2016 Frontier Pharma: Chronic ... First-in-Class Innovation Chronic Obstructive Pulmonary ... chronic inflammation of the airways and lungs. Persistent ... make the disease one of the leading causes ... in the world. COPD is linked to cumulative ...
(Date:2/4/2016)... 2016  AMRI (NASDAQ:  AMRI) today announced that Anthony ... President of Pfizer Global Supply, has been elected to the ... In addition, the Company announced that Mr. Gabe Leung ... 2010, has retired from the AMRI Board of Directors in ... business ventures.  William S. Marth , President ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Love is in the air at King Kullen! The ... and packaging. This staple for Valentine’s Day is a must-have, and can be picked ... Day, not only are long-stem roses available, but also other flower bouquets, elegantly wrapped ...
(Date:2/5/2016)... ... 05, 2016 , ... The event is being held on April 7, 2016 ... Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the care and ... Parkinson’s disease and is the architect of this informative event to raise awareness and ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... independent PROSHRED franchises from across the country gathered at the La Valencia Hotel ... top performers. PROSHRED Chicago was named the year’s most outstanding franchise, walking ...
(Date:2/5/2016)... SARASOTA, Fla., (PRWEB) , ... February 05, 2016 , ... ... appetizing recipes just in time for this weekend’s Big Game. Take the stress out ... ingredients that will keep your guests happy at every stage of the game. , ...
Breaking Medicine News(10 mins):